Related Experiment Video
Updated: Oct 8, 2025

Osmotic Drug Delivery to Ischemic Hindlimbs and Perfusion of Vasculature with Microfil for Micro-Computed Tomography Imaging
Published on: June 29, 2013
Combined Treatment With Hyperbaric Oxygen Therapy and Endovascular Therapy for Patients With Chronic Limb-Threatening
Yusuke Sato1, Kazushi Urasawa1, Tetsuji Morishita2
1Cardiovascular Center, Tokeidai Memorial Hospital Sapporo Japan.
Insights
Hyperbaric oxygen therapy (HBOT) combined with endovascular therapy (EVT) may improve wound healing in chronic limb-threatening ischemia (CLTI) patients. This study investigates HBOT
Area of Science:
- Vascular Surgery
- Hyperbaric Medicine
- Regenerative Medicine
Background:
- Chronic limb-threatening ischemia (CLTI) poses a significant risk of lower-limb amputation.
- Hyperbaric oxygen therapy (HBOT) is an adjunctive treatment option for CLTI.
- Current guidelines recommend HBOT alongside, not instead of, revascularization for CLTI.
Purpose of the Study:
- To evaluate the efficacy of HBOT when added to successful endovascular therapy (EVT) in CLTI patients.
- To assess the impact of HBOT on wound healing and limb salvage in CLTI.
- To determine if HBOT improves outcomes after EVT for CLTI.
Main Methods:
- A multicenter prospective randomized open blinded-endpoint trial (HOTFOOT study).
- 140 CLTI patients undergoing successful EVT will be randomized 1:1 to EVT+HBOT or EVT alone.
- Participants will receive 30 HBOT sessions over a 6-month follow-up period.
Main Results:
- Primary outcome: time to complete wound healing.
- Secondary outcomes: proportion of complete wound healing, freedom from major amputation, amputation-free survival, and target lesion reintervention.
- Data collection and analysis will occur over a 6-month follow-up period.
Conclusions:
- The study aims to determine if combining HBOT with EVT enhances lower-limb outcomes in CLTI patients.
- Findings will inform clinical practice regarding the use of HBOT as an adjunct therapy for CLTI.
- This research is expected to provide evidence on the role of HBOT in improving wound healing and preventing amputation in CLTI.
Abstract:
Hyperbaric oxygen therapy (HBOT) is regarded as one of the therapeutic options added to standard care to improve lower-limb outcomes in patients with chronic limb-threatening ischemia (CLTI). However, the current guidelines specify that HBOT should not be offered instead of revascularization to prevent limb loss in CLTI patients. The aim of the HOTFOOT study is to examine the impact of HBOT on wound healing in CLTI patients after successful endovascular therapy (EVT). The HOTFOOT study is a multicenter prospective randomized open blinded-endpoint trial that is to be conducted at 10 trial centers in Japan between February 2021 and February 2022. This study will enroll 140 patients with CLTI receiving successful EVT. Eligible participants will be allocated 1 : 1 to either the EVT+HBOT or EVT group; participants in the EVT+HBOT group will receive 30 HBOT sessions. The primary outcome is the time to complete wound healing over the 6-month follow-up. Secondary outcomes during the 6-month follow-up are the proportion of patients who achieved complete wound healing, freedom from major lower-limb amputation, amputation-free survival, and freedom from target lesion reintervention. This study is expects to assess whether HBOT, in combination with successful EVT, can improve lower-limb outcomes in CLTI patients.
More Related Videos
08:16High-Resolution Three-Dimensional Imaging of the Footpad Vasculature in a Murine Hindlimb Gangrene Model
Published on: March 16, 2022
07:25Predicting Amputation using Local Circulating Mononuclear Progenitor Cells in Angioplasty-treated Patients with Critical Limb Ischemia
Published on: September 22, 2020
Related Concept Videos
Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
Peripheral Artery Disease III: Interprofessional Care
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
Venous Thrombosis III: Interprofessional Care
Varicose Veins II: Diagnostic Studies and Interprofessional Care